Top

Supportive Care in Cancer

Published in:

01-04-2020 | Lung Cancer | Original Article

The usefulness and prognostic value of Memorial Symptom Assessment-Short Form and Condensed Memorial Symptom Assessment Scale in assessment of lung cancer patients

Authors: Haci Ahmet Bircan, Gonul Seven Yalcin, Sumeyye Fidanci, Adnan Karaibrahimoglu, Hatice Celik Tuglu

Published in: Supportive Care in Cancer | Issue 4/2020

Abstract

Purpose

Lung cancer is associated with high level of symptoms and patient-reported symptoms have been rarely used as a prognostic score to predict patients survival.

Methods

Frequency and burden of symptoms in lung cancer patients were evaluated before the diagnosis with the Memorial Symptom Assessment-Short Form (MSAS-SF) and Condensed Memorial Symptom Assessment Scale (CMSAS) questionnaires. Performance status, stage of disease, serum albumin, and C-reactive protein (CRP) levels were recorded. Patients were staged according to 8th TNM classification. A survival analysis was applied.

Results

The mean age of 116 patients (adenocarcinoma 51, squamous cell 43, non-small cell 5, small cell 17) was 65.2 ± 10.1 (28–87) years. The most common seen physical and psychological symptoms were cough (86.3%), lack of energy (74.3%), dyspnea (70.1%), and feeling sad (61.5%), feeling nervous (61.5%), and worrying (53.8%). Total and subscores of MSAS and CMSAS are significantly higher in M1 disease than M0 disease. All MSAS-SF and CMSAS scores, but not MSAS-PSYCH and CMSAS-PSYCH, positively correlated with age, high serum CRP, white blood cells/neutrophils counts, and TNM stage, and negatively correlated with albumin levels, performance status, and overall survival (OS). Median survival was 77, 195, 370, and 579 days for the four prognostic interquartile groups according to CMSAS-SUM score (p < 0.0001).

Conclusion

MSAS-SF and CMSAS questionnaires can be useful tool for discriminating metastatic from non-metastatic disease in treatment-naïve patients with lung cancer. Since both questionnaires well correlated with OS and important prognostic factors, they can use to plan palliative care and to help for predicting survival of lung cancer patients.

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29. https://doi.org/10.3322/caac.21208 CrossRefPubMed

Devesa SS, Bray F, Vizcaino AP, Parkin DM (2005) International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117:294–299. https://doi.org/10.1002/ijc.21183 CrossRefPubMed

Bircan HA, Gurbuz N, Pataer A, Caner A, Kahraman N, Bayraktar E, Bayraktar R, Erdogan MA, Kabil N, Ozpolat B (2018) Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. Lung Cancer 124:31–39. https://doi.org/10.1016/j.lungcan.2018.07.027 CrossRefPubMed

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V (2016) The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51. https://doi.org/10.1016/j.jtho.2015.09.009 CrossRefPubMed

Detterbeck FC, Postmus PE, Tanoue LT (2013) The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e191S–e210S. https://doi.org/10.1378/chest.12-2354 CrossRefPubMed

Dirican N, Dirican A, Anar C, Atalay S, Ozturk O, Bircan A, Akkaya A, Cakir M (2016) A new inflammatory prognostic index, based on C-reactive protein, the neutrophil to lymphocyte ratio and serum albumin is useful for predicting prognosis in non-small cell lung cancer cases. Asian Pac J Cancer Prev 17:5101–5106. https://doi.org/10.22034/APJCP.2016.17.12.5101 CrossRefPubMedPubMedCentral

Gu XB, Tian T, Tian XJ, Zhang XJ (2015) Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep 5:12493. https://doi.org/10.1038/srep12493 CrossRefPubMedPubMedCentral

Jafri SH, Previgliano C, Khandelwal K, Shi R (2015) Cachexia index in advanced non-small-cell lung cancer patients. Clin Med Insights Oncol 9:87–93. https://doi.org/10.4137/cmo.s30891 CrossRefPubMedPubMedCentral

Zhou T, Zhan J, Hong S, Hu Z, Fang W, Qin T, Ma Y, Yang Y, He X, Zhao Y, Huang Y, Zhao H, Zhang L (2015) Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer. Sci Rep 5:10481. https://doi.org/10.1038/srep10481 CrossRefPubMedPubMedCentral

10.

Rivas-Fuentes S, Salgado-Aguayo A, Pertuz Belloso S, Gorocica Rosete P, Alvarado-Vasquez N, Aquino-Jarquin G (2015) Role of chemokines in non-small cell lung cancer: angiogenesis and inflammation. J Cancer 6:938–952. https://doi.org/10.7150/jca.12286 CrossRefPubMedPubMedCentral

11.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495. https://doi.org/10.1016/s1470-2045(10)70218-7 CrossRefPubMed

12.

Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ (2014) Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 14:754–762. https://doi.org/10.1038/nrc3829 CrossRefPubMed

13.

Patel HJ, Patel BM (2017) TNF-alpha and cancer cachexia: molecular insights and clinical implications. Life Sci 170:56–63. https://doi.org/10.1016/j.lfs.2016.11.033 CrossRefPubMed

14.

Gulen ST, Karadag F, Karul AB, Kilicarslan N, Ceylan E, Kuman NK, Cildag O (2012) Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung 190:327–332. https://doi.org/10.1007/s00408-011-9364-6 CrossRefPubMed

15.

Okediji PT, Salako O, Fatiregun OO (2017) Pattern and predictors of unmet supportive care needs in cancer patients. Cureus 9:e1234. https://doi.org/10.7759/cureus.1234 CrossRefPubMedPubMedCentral

16.

McGee SF, Zhang T, Jonker H, Laurie SA, Goss G, Nicholas G, Albaimani K, Wheatley-Price P (2018) The impact of baseline Edmonton Symptom Assessment Scale scores on treatment and survival in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 19:e91–e99. https://doi.org/10.1016/j.cllc.2017.05.018 CrossRefPubMed

17.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMed

18.

Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A:635–642CrossRefPubMed

19.

Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L et al (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326–1336CrossRefPubMed

20.

Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT (2000) The memorial symptom assessment scale short form (MSAS-SF). Cancer 89:1162–1171CrossRefPubMed

21.

Chang VT, Hwang SS, Kasimis B, Thaler HT (2004) Shorter symptom assessment instruments: the Condensed Memorial Symptom Assessment Scale (CMSAS). Cancer Investig 22:526–536CrossRef

22.

Bouazza YB, Chiairi I, El Kharbouchi O, De Backer L, Vanhoutte G, Janssens A, Van Meerbeeck JP (2017) Patient-reported outcome measures (PROMs) in the management of lung cancer: a systematic review. Lung Cancer 113:140–151. https://doi.org/10.1016/j.lungcan.2017.09.011 CrossRefPubMed

23.

Eser S, Goksel T, Erbaycu AE, Baydur H, Basarik B, Yanik AO, Gursul KK, Celik P, Ediz EC, Hatipoglu O, Yayla BA, Baser S, Eser E (2016) Comparison of generic and lung cancer-specific quality of life instruments for predictive ability of survival in patients with advanced lung cancer. Springerplus 5:1833. https://doi.org/10.1186/s40064-016-3492-7 CrossRefPubMedPubMedCentral

24.

Chang VT, Scott CB, Gonzalez ML, Einhorn J, Yan H, Kasimis BS (2015) Patient-reported outcomes for determining prognostic groups in veterans with advanced cancer. J Pain Symptom Manag 50:313–320. https://doi.org/10.1016/j.jpainsymman.2015.03.016 CrossRef

25.

Quinten C, Maringwa J, Gotay CC, Martinelli F, Coens C, Reeve BB, Flechtner H, Greimel E, King M, Osoba D, Cleeland C, Ringash J, Schmucker-Von Koch J, Taphoorn MJ, Weis J, Bottomley A (2011) Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 103:1851–1858. https://doi.org/10.1093/jnci/djr485 CrossRefPubMedPubMedCentral

26.

Yuceege M, Sanisoglu B, Firat H, Ersoy Y, Sevgi E, Kurt EB (2015) The clinical utility of Memorial Symptom Assessment-Short Form and Condensed Memorial Symptom Assessment Scale in Turkish lung cancer patients. Clin Respir J 9:221–227. https://doi.org/10.1111/crj.12127 CrossRefPubMed

27.

Yildirim Y, Tokem Y, Bozkurt N, Fadiloglu C, Uyar M, Uslu R (2011) Reliability and validity of the Turkish version of the Memorial Symptom Assessment Scale in cancer patients. Asian Pac J Cancer Prev 12:3389–3396PubMed

28.

Akin S, Can G, Aydiner A, Ozdilli K, Durna Z (2010) Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. Eur J Oncol Nurs 14:400–409. https://doi.org/10.1016/j.ejon.2010.01.003 CrossRefPubMed

29.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655CrossRefPubMed

30.

Niibe Y, Chang JY, Onishi H, Salama J, Hiraki T, Yamashita H (2013) Oligometastases/oligo-recurrence of lung cancer. Pulm Med 2013:438236. https://doi.org/10.1155/2013/438236 CrossRefPubMedPubMedCentral

31.

Milano MT VE, West HJ, Salama JK (2019) Oligometastatic non-small cell lung cancer.

32.

Beckles MA, Spiro SG, Colice GL, Rudd RM (2003) Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest 123:97S–104SCrossRefPubMed

33.

Midthun D (2018) Overview of the risk factors, pathology, and clinical manifestations of lung cancer. (ed)^(eds)

34.

Mendoza TR, Kehl KL, Bamidele O, Williams LA, Shi Q, Cleeland CS, Simon G (2019) Assessment of baseline symptom burden in treatment-naive patients with lung cancer: an observational study. Support Care Cancer. https://doi.org/10.1007/s00520-018-4632-0 CrossRefPubMed

35.

Bulbul Y, Ozlu T, Arinc S, Ozyurek BA, Gunbatar H, Senturk A, Bahadir A, Ozcelik M, Yilmaz U, Akbay MO, Saglam L, Kilic T, Kirkil G, Ozcelik N, Tatar D, Baris SA, Yavsan DM, Sen HS, Berk S, Acat M, Cakmak G, Yumuk PF, Intepe YS, Toru U, Ayik SO, Basyigit I, Ozkurt S, Mutlu LC, Yasar ZA, Esme H, Erol MM, Oruc O, Erdogan Y, Asker S, Ulas A, Erol S, Kerget B, Erbaycu AE, Teke T, Besiroglu M, Can H, Dalli A, Talay F (2017) Assessment of palliative care in lung cancer in Turkey. Med Princ Pract 26:50–56. https://doi.org/10.1159/000452801 CrossRefPubMed

36.

Goksel T, Akkoclu A (2002) Pattern of lung cancer in Turkey, 1994–1998. Respiration 69:207–210. https://doi.org/10.1159/000063621 CrossRefPubMed

37.

Ministry of Health General Directorate of Primary Health Care GATS (2010) Turkey Report, 2010

38.

Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferrau F, Frontini L, Bearz A, Repetto L, Gridelli C, Barletta E, Barzelloni ML, Iaffaioli RV, De Maio E, Di Maio M, De Feo G, Sigoriello G, Chiodini P, Cioffi A, Guardasole V, Angelini V, Rossi A, Bilancia D, Germano D, Lamberti A, Pontillo V, Brancaccio L, Renda F, Romano F, Esani G, Gambaro A, Vinante O, Azzarello G, Clerici M, Bollina R, Belloni P, Sannicolo M, Ciuffreda L, Parello G, Cabiddu M, Sacco C, Sibau A, Porcile G, Castiglione F, Ostellino O, Monfardini S, Stefani M, Scagliotti G, Selvaggi G, De Marinis F, Martelli O, Gasparini G, Morabito A, Gattuso D, Colucci G, Galetta D, Giotta F, Gebbia V, Borsellino N, Testa A, Malaponte E, Capuano MA, Angiolillo M, Sollitto F, Tirelli U, Spazzapan S, Adamo V, Altavilla G, Scimone A, Hopps MR, Tartamella F, Ianniello GP, Tinessa V, Failla G, Bordonaro R, Gebbia N, Valerio MR, D’Aprile M, Veltri E, Tonato M, Darwish S, Romito S, Carrozza F, Barni S, Ardizzoia A, Corradini GM, Pavia G, Belli M, Colantuoni G, Galligioni E, Caffo O, Labianca R, Quadri A, Cortesi E, D’Auria G, Fava S, Calcagno A, Luporini G, Locatelli MC, Di Costanzo F, Gasperoni S, Isa L, Candido P, Gaion F, Palazzolo G, Nettis G, Annamaria A, Rinaldi M, Lopez M, Felletti R, Di Negro GB, Rossi N, Calandriello A, Maiorino L, Mattioli R, Celano A, Schiavon S, Illiano A, Raucci CA, Caruso M, Foa P, Tonini G, Curcio C, Cazzaniga M (2005) Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23:6865–6872. https://doi.org/10.1200/jco.2005.02.527 CrossRefPubMed

39.

Barney BJ, Wang XS, Lu C, Liao Z, Johnson VE, Cleeland CS, Mendoza TR (2013) Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer. Qual Life Res 22:2143–2150. https://doi.org/10.1007/s11136-013-0356-2 CrossRefPubMed

40.

von Meyenfeldt M (2005) Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs 9(Suppl 2):S35–S38. https://doi.org/10.1016/j.ejon.2005.09.001 CrossRef

41.

Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69. https://doi.org/10.1186/1475-2891-9-69 CrossRefPubMedPubMedCentral

42.

Espinosa E, Feliu J, Zamora P, Gonzalez Baron M, Sanchez JJ, Ordon ez A, Espinosa J (1995) Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 12:67–76CrossRefPubMed

43.

McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39:210–213. https://doi.org/10.1207/S15327914nc392_8 CrossRefPubMed

44.

Miyazaki T, Yamasaki N, Tsuchiya T, Matsumoto K, Kunizaki M, Kamohara R, Hatachi G, Doi R, Obata T, Nagayasu T (2017) Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. Surg Today 47:836–843. https://doi.org/10.1007/s00595-016-1448-8 CrossRefPubMed

45.

Go SI, Jeon H, Park SW, Kang MH, Kim HG, Lee GW (2018) Low pre-treatment nutritional index is significantly related to poor outcomes in small cell lung cancer. Thorac Cancer 9:1483–1491. https://doi.org/10.1111/1759-7714.12862 CrossRefPubMedPubMedCentral

46.

Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z (2010) Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24:968–974. https://doi.org/10.1016/j.bbi.2010.03.009 CrossRefPubMedPubMedCentral

47.

Kao SC, Vardy J, Harvie R, Chatfield M, van Zandwijk N, Clarke S, Pavlakis N (2013) Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer 21:697–705. https://doi.org/10.1007/s00520-012-1569-6 CrossRefPubMed

48.

Menezes JR, Luvisaro BMO, Rodrigues CF, Muzi CD, Guimaraes RM (2017) Test-retest reliability of Brazilian version of Memorial Symptom Assessment Scale for assessing symptoms in cancer patients. Einstein (Sao Paulo) 15:148–154. https://doi.org/10.1590/s1679-45082017ao3645 CrossRef

Title: The usefulness and prognostic value of Memorial Symptom Assessment-Short Form and Condensed Memorial Symptom Assessment Scale in assessment of lung cancer patients
Authors: Haci Ahmet Bircan
Gonul Seven Yalcin
Sumeyye Fidanci
Adnan Karaibrahimoglu
Hatice Celik Tuglu
Publication date: 01-04-2020
Publisher: Springer Berlin Heidelberg
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Dyspnea
Dyspnea
Published in: Supportive Care in Cancer / Issue 4/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-05003-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2020

Pain management index (PMI)—does it reflect cancer patients’ wish for focus on pain?

The efficacy of placebo for the treatment of cancer-related fatigue: a systematic review and meta-analysis

Longitudinal course and predictors of communication and affect management self-efficacy among women newly diagnosed with gynecological cancers

More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer

What is the evidence for mirtazapine in treating cancer-related symptomatology? A systematic review

Cancer survivors’ challenges with ostomy appliances and self-management: a qualitative analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer